The role of nebulized therapy in the management of COPD

Evidence and recommendations

Rajiv Dhand, Myrna Dolovich, Bradley Chipps, Timothy R. Myers, Ruben Restrepo, Judith Rosen Farrar

Research output: Contribution to journalReview article

37 Citations (Scopus)

Abstract

Current guidelines recommend inhalation therapy as the preferred route of drug administration for treating chronic obstructive pulmonary disease (COPD). Previous systematic reviews in COPD patients found similar clinical outcomes for drugs delivered by handheld inhalers - pressurized metered-dose inhalers (pMDIs), dry powder inhalers (DPIs) - and nebulizers, provided the devices were used correctly. However, in routine clinical practice critical errors in using handheld inhalers are highly prevalent and frequently result in inadequate symptom relief. In comparison with pMDIs and DPIs, effective drug delivery with conventional pneumatic nebulizers requires less intensive patient training. Moreover, by design, newer nebulizers are more portable and more efficient than traditional jet nebulizers. The current body of evidence regarding nebulizer use for maintenance therapy in patients with moderate-to-severe COPD, including use during exacerbations, suggests that the efficacy of long-term nebulizer therapy is similar, and in some respects superior, to that with pMDI/DPIs. Therefore, despite several known drawbacks associated with nebulized therapy, we recommend that maintenance therapy with nebulizers should be employed in elderly patients, those with severe disease and frequent exacerbations, and those with physical and/or cognitive limitations. Likewise, financial concerns and individual preferences that lead to better compliance may favor nebulized therapy over other inhalers. For some patients, using both nebulizers and pMDI/DPI may provide the best combination of efficacy and convenience. The impact of maintenance nebulizer treatment on other relevant clinical outcomes in patients with COPD, especially the progressive decline in lung function and frequency of exacerbations, needs further investigation.

Original languageEnglish (US)
Pages (from-to)58-72
Number of pages15
JournalCOPD: Journal of Chronic Obstructive Pulmonary Disease
Volume9
Issue number1
DOIs
StatePublished - Feb 1 2012
Externally publishedYes

Fingerprint

Nebulizers and Vaporizers
Chronic Obstructive Pulmonary Disease
Dry Powder Inhalers
Metered Dose Inhalers
Therapeutics
Drug Administration Routes
Respiratory Therapy
Pharmaceutical Preparations
Compliance
Disease Progression
Maintenance
Guidelines

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine

Cite this

The role of nebulized therapy in the management of COPD : Evidence and recommendations. / Dhand, Rajiv; Dolovich, Myrna; Chipps, Bradley; Myers, Timothy R.; Restrepo, Ruben; Rosen Farrar, Judith.

In: COPD: Journal of Chronic Obstructive Pulmonary Disease, Vol. 9, No. 1, 01.02.2012, p. 58-72.

Research output: Contribution to journalReview article

Dhand, Rajiv ; Dolovich, Myrna ; Chipps, Bradley ; Myers, Timothy R. ; Restrepo, Ruben ; Rosen Farrar, Judith. / The role of nebulized therapy in the management of COPD : Evidence and recommendations. In: COPD: Journal of Chronic Obstructive Pulmonary Disease. 2012 ; Vol. 9, No. 1. pp. 58-72.
@article{5d1e4922d3c34a259362e3d47bd28d2b,
title = "The role of nebulized therapy in the management of COPD: Evidence and recommendations",
abstract = "Current guidelines recommend inhalation therapy as the preferred route of drug administration for treating chronic obstructive pulmonary disease (COPD). Previous systematic reviews in COPD patients found similar clinical outcomes for drugs delivered by handheld inhalers - pressurized metered-dose inhalers (pMDIs), dry powder inhalers (DPIs) - and nebulizers, provided the devices were used correctly. However, in routine clinical practice critical errors in using handheld inhalers are highly prevalent and frequently result in inadequate symptom relief. In comparison with pMDIs and DPIs, effective drug delivery with conventional pneumatic nebulizers requires less intensive patient training. Moreover, by design, newer nebulizers are more portable and more efficient than traditional jet nebulizers. The current body of evidence regarding nebulizer use for maintenance therapy in patients with moderate-to-severe COPD, including use during exacerbations, suggests that the efficacy of long-term nebulizer therapy is similar, and in some respects superior, to that with pMDI/DPIs. Therefore, despite several known drawbacks associated with nebulized therapy, we recommend that maintenance therapy with nebulizers should be employed in elderly patients, those with severe disease and frequent exacerbations, and those with physical and/or cognitive limitations. Likewise, financial concerns and individual preferences that lead to better compliance may favor nebulized therapy over other inhalers. For some patients, using both nebulizers and pMDI/DPI may provide the best combination of efficacy and convenience. The impact of maintenance nebulizer treatment on other relevant clinical outcomes in patients with COPD, especially the progressive decline in lung function and frequency of exacerbations, needs further investigation.",
author = "Rajiv Dhand and Myrna Dolovich and Bradley Chipps and Myers, {Timothy R.} and Ruben Restrepo and {Rosen Farrar}, Judith",
year = "2012",
month = "2",
day = "1",
doi = "10.3109/15412555.2011.630047",
language = "English (US)",
volume = "9",
pages = "58--72",
journal = "COPD: Journal of Chronic Obstructive Pulmonary Disease",
issn = "1541-2555",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - The role of nebulized therapy in the management of COPD

T2 - Evidence and recommendations

AU - Dhand, Rajiv

AU - Dolovich, Myrna

AU - Chipps, Bradley

AU - Myers, Timothy R.

AU - Restrepo, Ruben

AU - Rosen Farrar, Judith

PY - 2012/2/1

Y1 - 2012/2/1

N2 - Current guidelines recommend inhalation therapy as the preferred route of drug administration for treating chronic obstructive pulmonary disease (COPD). Previous systematic reviews in COPD patients found similar clinical outcomes for drugs delivered by handheld inhalers - pressurized metered-dose inhalers (pMDIs), dry powder inhalers (DPIs) - and nebulizers, provided the devices were used correctly. However, in routine clinical practice critical errors in using handheld inhalers are highly prevalent and frequently result in inadequate symptom relief. In comparison with pMDIs and DPIs, effective drug delivery with conventional pneumatic nebulizers requires less intensive patient training. Moreover, by design, newer nebulizers are more portable and more efficient than traditional jet nebulizers. The current body of evidence regarding nebulizer use for maintenance therapy in patients with moderate-to-severe COPD, including use during exacerbations, suggests that the efficacy of long-term nebulizer therapy is similar, and in some respects superior, to that with pMDI/DPIs. Therefore, despite several known drawbacks associated with nebulized therapy, we recommend that maintenance therapy with nebulizers should be employed in elderly patients, those with severe disease and frequent exacerbations, and those with physical and/or cognitive limitations. Likewise, financial concerns and individual preferences that lead to better compliance may favor nebulized therapy over other inhalers. For some patients, using both nebulizers and pMDI/DPI may provide the best combination of efficacy and convenience. The impact of maintenance nebulizer treatment on other relevant clinical outcomes in patients with COPD, especially the progressive decline in lung function and frequency of exacerbations, needs further investigation.

AB - Current guidelines recommend inhalation therapy as the preferred route of drug administration for treating chronic obstructive pulmonary disease (COPD). Previous systematic reviews in COPD patients found similar clinical outcomes for drugs delivered by handheld inhalers - pressurized metered-dose inhalers (pMDIs), dry powder inhalers (DPIs) - and nebulizers, provided the devices were used correctly. However, in routine clinical practice critical errors in using handheld inhalers are highly prevalent and frequently result in inadequate symptom relief. In comparison with pMDIs and DPIs, effective drug delivery with conventional pneumatic nebulizers requires less intensive patient training. Moreover, by design, newer nebulizers are more portable and more efficient than traditional jet nebulizers. The current body of evidence regarding nebulizer use for maintenance therapy in patients with moderate-to-severe COPD, including use during exacerbations, suggests that the efficacy of long-term nebulizer therapy is similar, and in some respects superior, to that with pMDI/DPIs. Therefore, despite several known drawbacks associated with nebulized therapy, we recommend that maintenance therapy with nebulizers should be employed in elderly patients, those with severe disease and frequent exacerbations, and those with physical and/or cognitive limitations. Likewise, financial concerns and individual preferences that lead to better compliance may favor nebulized therapy over other inhalers. For some patients, using both nebulizers and pMDI/DPI may provide the best combination of efficacy and convenience. The impact of maintenance nebulizer treatment on other relevant clinical outcomes in patients with COPD, especially the progressive decline in lung function and frequency of exacerbations, needs further investigation.

UR - http://www.scopus.com/inward/record.url?scp=84856595409&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856595409&partnerID=8YFLogxK

U2 - 10.3109/15412555.2011.630047

DO - 10.3109/15412555.2011.630047

M3 - Review article

VL - 9

SP - 58

EP - 72

JO - COPD: Journal of Chronic Obstructive Pulmonary Disease

JF - COPD: Journal of Chronic Obstructive Pulmonary Disease

SN - 1541-2555

IS - 1

ER -